Abeona Therapeutics (NASDAQ: ABEO – Get Rating) and AbbVie (NYSE: ABBV – Get Rating) are both medical companies, but which is the better company? We will compare the two companies based on institutional ownership strength, risk, analyst recommendations, profitability, dividends, earnings and valuation.
This is a breakdown of the current recommendations and price targets for Abeona Therapeutics and AbbVie, as provided by MarketBeat.com.
|Sales Ratings||Hold odds||Buy reviews||Strong buy odds||Rating|
Abeona Therapeutics currently has a consensus price target of $49.00, indicating a potential upside of 1,109.88%. AbbVie has a consensus price target of $159.63, indicating a potential upside of 12.53%. Given Abeona Therapeutics’ higher consensus rating and higher upside potential, stock analysts clearly believe that Abeona Therapeutics is more favorable than AbbVie.
Volatility and risk
Abeona Therapeutics has a beta of 1.06, indicating that its stock price is 6% more volatile than the S&P 500. In comparison, AbbVie has a beta of 0.7, indicating that its stock price is 30% less volatile than the S&P 500.
This table compares the net margins, return on equity and return on assets of Abeona Therapeutics and AbbVie.
|Net margins||Return on equity||return on assets|
|Abeona Therapeutic||N / A||-115.37%||-70.59%|
Insider and Institutional Ownership
27.8% of Abeona Therapeutics shares are held by institutional investors. By comparison, 67.0% of AbbVie shares are held by institutional investors. 2.4% of Abeona Therapeutics shares are held by company insiders. By comparison, 0.1% of AbbVie shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds, and large money managers believe a company is poised for long-term growth.
Valuation and benefits
This table compares gross revenue, earnings per share (EPS), and valuation of Abeona Therapeutics and AbbVie.
|Gross revenue||Price/sales ratio||Net revenue||Earnings per share||Price/earnings ratio|
|Abeona Therapeutic||$3.00 million||8.03||-84.94 million dollars||($18.58)||-0.22|
|AbbVie||$56.20 billion||4.46||$11.54 billion||$7.06||20.09|
AbbVie has higher revenues and profits than Abeona Therapeutics. Abeona Therapeutics trades at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.
AbbVie beats Abeona Therapeutics on 9 out of 14 factors compared between the two stocks.
About Abeona Therapeutics
(Get an evaluation)
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, is focused on developing and delivering gene therapy products for serious and life-threatening rare diseases. The Company’s principal programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV-based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type B. It is also developing an ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for the treatment of childhood Batten disease; EB-201 for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach for a gene therapy program for rare blood diseases. Additionally, it is involved in the commercialization of MuGard, a mucoadhesive mouthwash for the management of mucositis, stomatitis, aphthous ulcers and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for the commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.
(Get an evaluation)
AbbVie Inc. discovers, develops, manufactures and sells pharmaceutical products worldwide. The Company offers HUMIRA, an injection therapy for autoimmune and intestinal Behçet’s disease; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1 to 6 infection. It also provides CREON, a pancreatic enzyme therapy for pancreatic exocrine insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Therapeutic Botox. In addition, the Company offers ORILISSA, a non-peptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriotic pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson’s disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for lowering IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Get news and reviews for Abeona Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Abeona Therapeutics and related companies with MarketBeat.com’s free daily email newsletter.